San Diego, CA — (PRESS RELEASE JET) — 09/26/2017 — An investigation on behalf of investors in NASDAQ:PTLA shares was announced concerning possible breaches of fiduciary duties by certain Portola Pharmaceuticals directors.
The investigation by a law firm concerns whether certain Portola Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
On September 5, 2017, Portola Pharmaceuticals Inc announced that the Company’s oral anticoagulant Bevyxxa (betrixaban) would launch in November 2017 at the earliest, and possibly as late as the first quarter of 2018. Having previously projected a September 2017 launch for Bevyxxa, Portola Pharmaceuticals Inc advised investors that the U.S. Food and Drug Administration would require additional time to complete review of a post-approval change to the product.
Those who purchased shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego
Powered by WPeMatico